文献速递肾移植血液净化与透析

肾移植与透析患者COVID-19相关死亡率:ERACODA协作研究结果

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

ERACODA数据库前瞻性纳入2020年2月1日至5月1日期间就诊的1073例肾移植或透析合并COVID-19患者,其中肾移植305例(28%)、透析768例(72%)。肾移植和透析患者28天死亡概率分别为21.3%(95%CI 14.3-30.2%)和25.0%(95%CI 20.2-30.0%);校正性别、年龄和衰弱后,住院死亡率无显著差异(HR 0.81,95%CI 0.59-1.10,P=0.18)。在透析等待移植患者中,移植后1年内患者死亡风险可能高于等待透析患者(校正HR 0.20,95%CI 0.07-0.56,P<0.01)。

要点

  • 肾移植和透析合并COVID-19患者28天死亡概率分别为21.3%和25.0%。
  • 校正性别、年龄和衰弱后,两者住院死亡率无显著差异(HR 0.81,P=0.18)。
  • 移植后1年内患者COVID-19相关死亡风险可能高于等待移植透析患者。

核心结论

  • 肾移植和透析合并COVID-19患者28天病死率高,主要由年龄和衰弱驱动。
  • 移植后第一年内患者COVID-19相关死亡风险可能高于等待移植的透析患者。

研究设计与样本

  • ERACODA前瞻性数据库纳入2020年2月1日至5月1日就诊的肾移植或透析合并COVID-19患者。
  • 共纳入1073例,肾移植305例(28%),透析768例(72%)。

主要发现

  • 肾移植和透析患者平均年龄分别为60±13岁和67±14岁。
  • 肾移植患者28天死亡概率21.3%(95%CI 14.3-30.2%),透析患者25.0%(95%CI 20.2-30.0%)。
  • 肾移植患者死亡主要与高龄相关,透析患者与年龄和衰弱相关。
  • 校正性别、年龄和衰弱后,住院死亡率无显著差异(HR 0.81,95%CI 0.59-1.10,P=0.18)。
  • 等待移植透析患者(n=148)28天内死亡8例,移植后1年内患者(n=23)死亡7例,校正HR 0.20(95%CI 0.07-0.56,P<0.01)。

临床怎么用

  • 对肾移植和透析合并COVID-19患者应重视年龄和衰弱评估以识别高危人群。
  • 临床决策需考虑移植后第一年内COVID-19相关死亡风险可能增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. METHODS: We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. RESULTS: Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3-30.2%] in kidney transplant and 25.0% (95% CI 20.2-30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59-1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation <1 year before presentation (HR adjusted for sex, age and frailty 0.20, 95% CI 0.07-0.56, P < 0.01). CONCLUSIONS: The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hilbrands LB, Duivenvoorden R, Vart P, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020. PMID: 33151337. doi:10.1093/ndt/gfaa261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。